Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.35 |
| ▸ | ITGAV | P06756 | 5/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 4/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306301 | 0.88 | DHODH (0.42) | DHODHRAF1BRAFPRKCIMAPK1 | |
| SCHEMBL18306335 | 0.81 | DHODH (0.38) | DHODHMAPK1 | |
| SCHEMBL18712023 | 0.80 | ROCK2 (0.42) | DHODHCDK8 | |
| SCHEMBL17177314 | 0.79 | DHODH (0.36) | DHODH | |
| SCHEMBL17177309 | 0.78 | DHODH (0.33) | DHODH | |
| SCHEMBL19661563 | 0.73 | MEN1 (0.40) | MAPTKDRRAF1BRAFMAPK1 | |
| SCHEMBL18306347 | 0.69 | ADORA2B (0.34) | — | |
| SCHEMBL18306350 | 0.68 | TGFBR1 (0.39) | HDAC3HDAC1HDAC2KDRCDK8 | |
| SCHEMBL17177311 | 0.67 | BTK (0.41) | MAPTRAF1MAPK1 | |
| SCHEMBL18712089 | 0.67 | ROCK1 (0.46) | KDRCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | DHODH 1945/4885ITGB3 462/4885ITGAV 1297/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | DHODH 4754/4885ITGB3 1957/4885ITGAV 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.